Glucose Vantive

Glucose Vantive is a solution for injection that contains glucose as the sole active ingredient. It is supplied in an unspecified strength and is intended for intravenous administration. Marketed in the European Union, this prescription‑only product is classified as an excipient/solvent and is used primarily as part of parenteral nutrition or to correct low blood‑sugar levels. The formulation provides a available source of energy when delivered directly into the bloodstream.

Glucose Vantive is indicated for several clinical situations where rapid delivery of carbohydrate energy or fluid replacement is required.

- Management of acute hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in perioperative or critical‑care settings. - Dilution medium for compatible intravenous medications. - Support during prolonged fasting or metabolic stress. - Provision of glucose for patients undergoing dialysis who require additional caloric input. - Use in pediatric patients for maintenance of blood glucose during surgery.

When administered intravenously, Glucose Vantive may be associated with a range of physiological responses. Most are mild and transient, while a few can be serious and require medical attention.

Common: - Transient increase in blood glucose level. - Mild hyperosmolarity causing temporary thirst. - Local irritation at the injection site. - Nausea or mild abdominal discomfort. - Headache or dizziness. - Temporary rise in serum osmolality. - Mild flushing. - Transient increase in urine output.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Electrolyte imbalance, particularly hyponatremia or hyperkalemia. - Hypersensitivity reactions such as rash, urticaria, or anaphylaxis. - Cardiovascular instability such as hypotension or arrhythmia. - Metabolic acidosis in patients with impaired renal function.

Glucose Vantive should be used with careful clinical assessment, and several precautions are recommended to minimize risks.

- Verify patient’s blood glucose level before administration to avoid excessive hyperglycemia. - Adjust infusion rate based on individual fluid and electrolyte needs. - Monitor serum electrolytes, especially sodium and potassium, during and after therapy. - Use aseptic technique to prevent contamination of the solution. - Assess for signs of hypersensitivity before each dose. - Avoid rapid bolus administration unless specifically indicated. - Consider reduced infusion rates in patients with cardiac failure or fluid overload. - Review renal function; accumulation may occur in severe impairment.

Glucose Vantive can interact with other intravenous agents or conditions that affect carbohydrate metabolism. Awareness of these interactions helps ensure safe co‑administration.

Avoid: - Co‑administration with other hypertonic glucose solutions, which may cause severe hyperglycemia. - Simultaneous infusion of insulin without appropriate glucose monitoring.

Use with caution: - Concurrent use of diuretics that may alter electrolyte balance. - Administration with beta‑adrenergic agonists, which can increase glucose production. - Use alongside sodium bicarbonate solutions, as combined osmolar load may affect fluid balance. - Overlap with total parenteral nutrition admixtures; monitor total carbohydrate load. - Caution when combined with medications that prolong QT interval, as rapid glucose shifts can affect cardiac electrophysiology.